Despite high-flying Gardasil sales, Merck executives see 'significant' opportunity ahead

Despite high-flying Gardasil sales, Merck executives see 'significant' opportunity ahead

Source: 
Fierce Pharma
snippet: 

When Merck reported second-quarter results last week, many pharma watchers tuned in to the fact that its blockbuster cancer fighter Keytruda finally passed market rival Opdivo in quarterly sales. Meanwhile, the company's big-selling HPV shot, Gardasil, continued to gain steam, and executives see "significant" opportunity for growth ahead for the vaccine.